Ascletis Pharma Inc
HKEX:1672
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.78
1.96
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gross Margin
Ascletis Pharma Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | CN |
Market Cap | 1.6B HKD |
Gross Margin |
-125%
|
Country | FR |
Market Cap | 6T USD |
Gross Margin |
0%
|
Country | US |
Market Cap | 320.1B USD |
Gross Margin |
67%
|
Country | US |
Market Cap | 147.4B USD |
Gross Margin |
60%
|
Country | US |
Market Cap | 119.4B USD |
Gross Margin |
86%
|
Country | US |
Market Cap | 113.8B USD |
Gross Margin |
78%
|
Country | US |
Market Cap | 94.1B EUR |
Gross Margin |
76%
|
Country | AU |
Market Cap | 135.4B AUD |
Gross Margin |
52%
|
Country | US |
Market Cap | 82.6B USD |
Gross Margin |
87%
|
Country | US |
Market Cap | 39.3B EUR |
Gross Margin |
75%
|
Country | NL |
Market Cap | 34.3B EUR |
Gross Margin |
89%
|
Ascletis Pharma Inc
Glance View
Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company is headquartered in Hangzhou, Zhejiang and currently employs 266 full-time employees. The company went IPO on 2018-08-01. The firm is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Ascletis Pharma Inc's most recent financial statements, the company has Gross Margin of -125.2%.